Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 35 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 10537560

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  2. US 10526346

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  3. US 10519153

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  4. US 10519133

    Vinyl compounds as FGFR and VEGFR inhibitors

    Medshine Discovery Inc. · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  5. US 10512673

    Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted
  6. US 10508106

    Bicyclic BET bromodomain inhibitors and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 17, 2019 · Expires Dec 12, 2039

    granted
  7. US 10508122

    Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 17, 2019 · Expires Dec 12, 2039

    granted
  8. US 10501444

    Inhibitors of influenza virus replication, application methods and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted
  9. US 10500194

    Covalent small molecule DCN1 inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted
  10. US 10501439

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted
  11. US 10494364

    Cathepsin K inhibitors and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  12. US 10485803

    Pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted
  13. US 10485800

    Mixed lineage kinase inhibitors for HIV/AIDS therapies

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted
  14. US 10479786

    Protein kinase inhibitors

    Princeton Drug Discovery, Inc · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  15. US 10478430

    Compounds useful as inhibitors of ATR kinase and combination therapies thereof

    Vertex Pharmaceuticals Incorporated · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  16. US 10478435

    Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  17. US 10479784

    Substituted pyrazin-2-amines as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  18. US 10471061

    Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  19. US 10471051

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  20. US 10471055

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  21. US 10472387

    Inhibitors of glucocorticoid receptor

    ORIC PHARMACEUTICALS, INC. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  22. US 2019337950

    BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS

    BIAL PORTELA & Cª S A [PT] · Granted Nov 7, 2019 · Expires Nov 2, 2039

    granted
  23. US 10463652

    Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

    VTV THERAPEUTICS LLC · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  24. US 10463663

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted